Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into the clinic, including candidates against Lyme disease and the chikungunya virus.

Valneva’s strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. Valneva aims to build a leading vaccines company with a portfolio of specialized assets targeting diseases with limited preventive or therapeutic treatment options.